Literature DB >> 16940878

Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea.

Nayoung Kim1, Jung Mogg Kim, Chung Hyun Kim, Young Soo Park, Dong Ho Lee, Joo Sung Kim, Hyun Chae Jung, In Sung Song.   

Abstract

GOALS: This study was performed to evaluate whether the prevalence rates of primary antibiotic resistance in Helicobacter pylori isolates could be different between 2 institutions, which are located in the different areas in Korea, and to evaluate the effect of antibiotic resistance on the eradication rate of H. pylori. STUDY: H. pylori were isolated from gastric mucosal biopsy specimens obtained from 113 Koreans, who did not have any eradication history. The susceptibilities of the H. pylori isolates to amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and moxifloxacin were examined according to the agar dilution method by 1 technician.
RESULTS: All of these patients were treated with the same regimen, proton pump inhibitor-amoxicillin-clarithromycin triple therapy. There was a statistical difference in resistance to metronidazole, levofloxacin, and moxifloxacin among 6 antibiotics between 2 institutions located in Seoul and Gyeonggi province. The rates of eradication were 94.2% for the clarithromycin and amoxicillin-susceptible strains, and 42.8% for the amoxicillin-susceptible and clarithromycin-resistant strains. In contrast, eradication rate was 100% for the amoxicillin-resistant strains.
CONCLUSIONS: These results show that there is institutional difference of antibiotic resistance of H. pylori, explaining the institutional difference of eradication rate of H. pylori. The resistance to clarithromycin seems to be an important determinant for the eradication by proton pump inhibitor triple therapy but resistance to amoxicillin does not have any effect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940878     DOI: 10.1097/00004836-200609000-00004

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  29 in total

1.  Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic.

Authors:  Muhammad Miftahussurur; Modesto Cruz; Phawinee Subsomwong; José A Jiménez Abreu; Celso Hosking; Hiroyuki Nagashima; Junko Akada; Yoshio Yamaoka
Journal:  Am J Trop Med Hyg       Date:  2017-02-13       Impact factor: 2.345

2.  The correlation of endoscopic and histological diagnosis of gastric atrophy.

Authors:  Alisher Eshmuratov; Jong Chun Nah; Nayoung Kim; Hye Seung Lee; Hee Eun Lee; Byoung Hwan Lee; Min Sik Uhm; Young Soo Park; Dong Ho Lee; Hyun Chae Jung; In Sung Song
Journal:  Dig Dis Sci       Date:  2009-07-23       Impact factor: 3.199

3.  Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection.

Authors:  Chang Seok Bang; Hyun Lim; Hae Min Jeong; Woon Geon Shin; Jae Ho Choi; Jae Seung Soh; Ho Suk Kang; Young Joo Yang; Ji Taek Hong; Suk Pyo Shin; Ki Tae Suk; Jae Jun Lee; Gwang Ho Baik; Dong Joon Kim
Journal:  Gut Microbes       Date:  2020-05-02

4.  Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

5.  Trends in the eradication rates of Helicobacter pylori infection for eleven years.

Authors:  Jai Hoon Yoon; Gwang Ho Baik; Kyoung Min Sohn; Dae Yong Kim; Yeon Soo Kim; Ki Tae Suk; Jin Bong Kim; Dong Joon Kim; Jin Bae Kim; Woon Geon Shin; Hak Yang Kim; Il Hyun Baik; Hyun Joo Jang
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

6.  Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

7.  Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

8.  Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.

Authors:  Hyuk Soon Choi; Hoon Jai Chun; Sang Hoon Park; Bora Keum; Yeon Seok Seo; Yong Sik Kim; Yoon-Tae Jeen; Soon Ho Um; Hong Sik Lee; Chang Duck Kim; Ho Sang Ryu
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

9.  Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance.

Authors:  Ju Yup Lee; Nayoung Kim; Min Soo Kim; Yoon Jin Choi; Jung Won Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Hyun Chae Jung
Journal:  Dig Dis Sci       Date:  2014-03-06       Impact factor: 3.199

Review 10.  Effect of bacterial and host factors on Helicobacter pylori eradication therapy.

Authors:  Takahiro Uotani; Muhammad Miftahussurur; Yoshio Yamaoka
Journal:  Expert Opin Ther Targets       Date:  2015-08-06       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.